Anti-Globalism Policy Cannot Stifle International Cooperation, US FDA’s Califf Says

 
• By Derrick Gingery
  
Generate a summary of this article
Listen to this article
Beta

The FDA commissioner said that supply chains will remain interconnected no matter how much nationalism dominates the political landscape, meaning international cooperation will still be necessary.

international cooperation
Australia TGA official says regulators shouldn't look for logic in some political positions and remain focused on providing safe and effective medicines. • Source: Shutterstock

SAN DIEGO – The pharmaceutical industry likely will remain dependent on worldwide operations despite rising political opposition to globalization, US Food and Drug Administration Commissioner Robert Califf said, which necessitates continued coordination with foreign regulators.

Key Takeaways

  • Supply chains already are connected and likely will stay that way despite the push against globalization, Califf said.

“We’re interdigitated whether people like it or not,” Califf said 19 June during the DIA Global Annual Meeting. “Just look...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from DIA

US FDA Not Ready For Sponsors Citing Others’ Platforms Yet, Marks Says

 
• By Derrick Gingery

Many platform designation requests have been from sponsors eager to cite other sponsors’ products, but CBER Director Peter Marks said in an interview with the Pink Sheet his office likely is years away from accepting those applications.

Project Optimus: Sponsors Register Concerns, Questions

 
• By Derrick Gingery

Meeting requests related to the Oncology Center of Excellence’s new dose optimization approach are increasing, along with sponsor questions, prompting the US FDA to determine how to clarify its intentions.

Anti-Globalism Policy Cannot Stifle International Cooperation, US FDA’s Califf Says

 
• By Derrick Gingery

The FDA commissioner said that supply chains will remain interconnected no matter how much nationalism dominates the political landscape, meaning international cooperation will still be necessary.

US FDA Creating Rare Disease ‘Hub’ To Serve As Center Of Excellence

 
• By Derrick Gingery

While not brandishing the name advocates have pushed for many years, the rare disease hub will play much the same role as a center of excellence in increasing collaboration between experts in the FDA drug and biologics centers.

More from Conferences

US FDA Creating Rare Disease ‘Hub’ To Serve As Center Of Excellence

 
• By Derrick Gingery

While not brandishing the name advocates have pushed for many years, the rare disease hub will play much the same role as a center of excellence in increasing collaboration between experts in the FDA drug and biologics centers.

Clinical Trial Diversity Action Plan Waivers Will Be ‘Very Rare,’ US FDA Official Says

 
• By Nielsen Hobbs

With the much-anticipated guidance still pending, OCE’s Tamy Kim reminds industry of the requirements and timing around avoiding the soon-to-be requirements on study enrollments.

US FDA Commissioner Robert Califf Says No Formulas For Trial Diversity

 
• By Sarah Karlin-Smith

The FDA does not appear likely to provide a calculation for sponsors to show clinical trial diversity, but agency officials seem split on how tough to enforce the new regulations intended to ensure all groups are adequately represented.